| Budget Amount *help |
¥45,370,000 (Direct Cost: ¥34,900,000、Indirect Cost: ¥10,470,000)
Fiscal Year 2018: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2017: ¥12,870,000 (Direct Cost: ¥9,900,000、Indirect Cost: ¥2,970,000)
Fiscal Year 2016: ¥14,690,000 (Direct Cost: ¥11,300,000、Indirect Cost: ¥3,390,000)
Fiscal Year 2015: ¥10,790,000 (Direct Cost: ¥8,300,000、Indirect Cost: ¥2,490,000)
|
|---|
| Outline of Final Research Achievements |
Neuropathic pain is a highly debilitating chronic pain condition that occurs after nerve damage. The underlying mechanisms remain unclear, and currently available treatments even morphine are frequently ineffective. We have previously demonstrated that spinal cord microglia are activated relatively soon after nerve injury and play an important role in the development of neuropathic pain. In this study, we identified a subset of microglia, CD11c+ cells, that are activated from a later phase of neuropathic pain. Using mice ablating these microglia or lacking a gene expressed in this subset, we found that these mice did not show such spontaneous recovery of neuropathic pain. These findings suggest that spinal cord microglia are heterogeneous and that CD11c+ microglia are a subset that has a novel role in resolving neuropathic pain.
|
